THE TGA has updated its processes for receiving serious unexpected adverse reaction (SUSAR) reports for unapproved medicines and biologicals used in clinical trials under the Clinical Trials Notification (CTN) or Clinical Trials Exemption (CTX) schemes.
Visit tga.gov.au for details.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Apr 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Apr 17